Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers


The solution


Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.


News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care

Gate2Brain at MIT Pitch Day at University of Cambridge

Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day at the University…
medicines beyond barriersG2B

Medicines beyond barriers

At Gate2Brain, we have found the key to unlocking the gate to the brain . We have developed a unique…
EITHealth Catapult 2022eithealth

Gate2Brain semifinalist of EITHealth’s Catapult 2022

We’re proud to share that Gate2Brain is semifinalist of EITHealth's Catapult 2022.Thanks to…
Una tecnología para ayudar a tratar el cáncer infantilgate2brain

A technology to help treat pediatric cancer

Una tecnología para ayudar a tratar el cáncer infantilExpansión. Madrid. La tecnología de…
Gate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series, a @Biocat initiative co-organized by the Delegation of the Government of Catalonia in Switzerland, The aim of the meeting is to put the best projects - from companies and/or research organizations - in contact with investors, business angels, venture capitalists and leading Swiss companies.

Gate2Brain will be attending The Investment Readiness Series

On the 4th of July, Gate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series,…

Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck

Meritxell Teixidó: “Una gran quantitat de fàrmacs no arriben al cervell, i la tecnologia de Gate2Brain…
Gate2Brain is delighted to be attending next week's #AseBioInvestorDay2022, organised by Asociación Española de Bioempresas in Madrid.Gate2Brain

Gate2Brain attending Asebio Investor Day 2022

Gate2Brain is delighted to be attending next week's #AseBioInvestorDay2022, organised by Asociación…
This past October, the i4KIDS Pediatric Innovation Hub hosted the Pediatric Innovation Day. Here is a video from Gate2Brain introducing its technology for pediatric brain tumors as one of the six finalist projects in the innovation competition. This fantastic and valuable initiative is organized by i4KIDS, an innovation-support Hub intended to identify pediatric and maternal health projects with the greatest potential in order to bring them closer to the market. The Hub is coordinated by Sant Joan de Déu Barcelona Children’s Hospital, In 2021, the #PediatricInnovationDay showcased some of the many innovative and challenging projects that are currently carried out in the field of pediatrics.

Gate2Brain Finalist Project at i4KIDS

This past October, the i4KIDS Pediatric Innovation Hub hosted the Pediatric Innovation Day. Here is…

‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer

Estas proteínas 'tractor' remolcan los fármacos hasta el cerebro como terapia contra un cáncer infantil…
Els valors de la Universitat La UB reivindica la seva identitatUniversitat de Barcelona

Gate2Brain’s CEO part of the values campaign of the University of Barcelona under the motto “I am Innovative”

Els valors de la Universitat La UB reivindica la seva identitat El transport públic, els mitjans de…


Making therapies a reality for patients by addressing unmet medical needs.


Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain